Pfizer Admits Myocarditis Risk for 5-12 Year-Olds Requires 5-Year Study
Clinical trials conducted by drug giant Pfizer were too short to determine long-term myocarditis risks in children who take the Covid-19 vaccine, the company admitted in documents submitted to the FDA.
The information appears on page 11 of an FDA advisory committee briefing from late last month, where Pfizer even admits its sample size of clinical trial volunteers was also too small to detect myocarditis risks in children aged 5 to 12.
More Here:
